3-(4-甲氧基苯基)氮杂丁烷 | 7215-07-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 中文名称: 3-(4-甲氧基苯基)氮杂丁烷
• 中文别名: 3-(4-甲氧基苯基)氮杂环丁烷
• 英文名称: 3-<4-Methoxy-phenyl>-azetidin
• 英文别名: 3-(4-Methoxy-phenyl)-azetidin；3-(4-methoxy-phenyl)-azetidine；3-(4-Methoxyphenyl)azetidine
• CAS: 7215-07-8
• 化学式: C₁₀H₁₃NO
• 分子量: 163.219
• InChiKey: JBMISQBTERXMTI-UHFFFAOYSA-N

物化性质

• 熔点：
  85-95℃
• 沸点：
  274℃
• 密度：
  1.051
• 闪点：
  106℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-(4-甲氧基苯基)氮杂丁烷 、 5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (5-Amino-3,4-dimethylthieno[2,3-c]pyridazin-6-yl)-[3-(4-methoxyphenyl)azetidin-1-yl]methanone
  参考文献：
  名称：

  Challenges in the development of an M 4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides

  摘要：

  Herein we describe the continued optimization of M-4 positive allosteric modulators (PAMs) within the 5-amino-thieno[2,3-c] pyridazine series of compounds. In this letter, we disclose our studies on tertiary amides derived from substituted azetidines. This series provided excellent CNS penetration, which had been challenging to consistently achieve in other amide series. Efforts to mitigate high clearance, aided by metabolic softspot analysis, were unsuccessful and precluded this series from further consideration as a preclinical candidate. In the course of this study, we found that potassium tetrafluoroborate salts could be engaged in a tosyl hydrazone reductive cross coupling reaction, a previously unreported transformation, which expands the synthetic utility of the methodology. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.10.053
• 作为产物：
  描述：

  tert-butyl 3-(4-methoxyphenyl)azetidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 3-(4-甲氧基苯基)氮杂丁烷
  参考文献：
  名称：

  Challenges in the development of an M 4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides

  摘要：

  Herein we describe the continued optimization of M-4 positive allosteric modulators (PAMs) within the 5-amino-thieno[2,3-c] pyridazine series of compounds. In this letter, we disclose our studies on tertiary amides derived from substituted azetidines. This series provided excellent CNS penetration, which had been challenging to consistently achieve in other amide series. Efforts to mitigate high clearance, aided by metabolic softspot analysis, were unsuccessful and precluded this series from further consideration as a preclinical candidate. In the course of this study, we found that potassium tetrafluoroborate salts could be engaged in a tosyl hydrazone reductive cross coupling reaction, a previously unreported transformation, which expands the synthetic utility of the methodology. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.10.053

文献信息

• Selective NR2B Antagonists
  申请人：Bristol-Myers Squibb Company

  公开号：US20150191452A1

  公开（公告）日：2015-07-09

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

  该披露通常涉及到I式化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是NR2B受体的配体，可能对治疗中枢神经系统的各种疾病有用。
• Synthesis of Novel Hydroxymethyl-Substituted Fused Heterocycles
  作者：Jane Holmes、Thomas McGuire、Lynsie Almeida、Bernard Barlaam、Rosemary Croft、Allan Dishington、Laksmaiah Gingipalli、Lorraine Hassall、Janet Hawkins、Stephanos Ioannidis、Jeffrey Johannes、Jane Moore、Anil Patel、Kurt Pike、Timothy Pontz、Xiaoyun Wu、Tao Wang、Hai-Jun Zhang、Xiaolan Zheng

  DOI：10.1055/s-0035-1561355

  日期：——

  ◊ Current address: AstraZeneca R&D, Darwin Building (310), Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK Abstract Examples of hydroxymethylated analogues of heteroaryl cores such as quinazolin-4-ones, isoquinolin-1(2H)-ones, pyrido[3,4-d]pyrimidin-4(3H)-ones, chromen-4-ones and pyrrolo[2,1-f][1,2,4]triazin-4(3H)-ones are sparse or non-existent in the scientific literature. We have demonstrated

  ◊当前地址：英国剑桥CB4 0WG，剑桥米尔顿路，剑桥科学园，达尔文大厦（310），阿斯利康研发中心 抽象的 杂芳基核的羟甲基化类似物的实例，例如喹唑啉-4-酮，异喹啉-1（2 H）-酮，吡啶并[3,4- d ]嘧啶-4（3 H）-酮，铬-4-酮和吡咯烷酮[2,1- f ] [1,2,4]三嗪-4（3 H）-在科学文献中稀疏或不存在。我们已经证明，通过使用标准程序，可以从容易获得的原材料中获得此类化合物。 杂芳基核的羟甲基化类似物的实例，例如喹唑啉-4-酮，异喹啉-1（2 H）-酮，吡啶并[3,4- d ]嘧啶-4（3 H）-酮，铬-4-酮和吡咯烷酮[2,1- f ] [1,2,4]三嗪-4（3 H）-在科学文献中稀疏或不存在。我们已经证明，通过使用标准程序，可以从容易获得的原材料中获得此类化合物。
• [EN] PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE<br/>[FR] INHIBITEURS DE PDE9 COMPRENANT UN SQUELETTE IMIDAZOTRIAZINONE
  申请人：LUNDBECK & CO AS H

  公开号：WO2013110768A1

  公开（公告）日：2013-08-01

  This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a compound of formula(l) for use in a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).

  这项发明涉及一类PDE9酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式(I)化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者施用式(I)化合物的治疗有效量。本发明还提供了一种式(I)化合物，用于治疗患有精神障碍的受试者的方法，包括向受试者施用式(I)化合物的治疗有效量。
• PDE9 inhibitors with imidazo triazinone backbone
  申请人：H. Lundbeck A/S

  公开号：US20150045348A1

  公开（公告）日：2015-02-12

  This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).

  这项发明涉及一类PDE9酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式(I)化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者施用式(I)化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者施用式(I)化合物的治疗有效量。
• [EN] CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE 2,4-DIOXOPYRIMIDINE INHIBANT CD73
  申请人：GILEAD SCIENCES INC

  公开号：WO2021222522A1

  公开（公告）日：2021-11-04

  The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.

  本公开提供了嘧啶二酮类化合物及其药物组合物，用于治疗癌症，包括实体肿瘤。这些化合物可以单独使用或与其他抗癌药物联合使用。